THX Pharma strengthens its financial position as of December 31, 2025

Biopharmaceutical company THX Pharma has revealed its cash position, which stands at €7,764,000 at the end of 2025, a significant increase compared to the €1,979,000 recorded in September of the same year. This financial boost is primarily due to a strategic agreement with Biocodex. This partnership includes an initial payment of €12 million in March 2026, bringing the pro forma cash position to €21.7 million.

This development allows THX Pharma to realize its strategy focused on the Batten-1 program and the TX01 product. The agreement with Biocodex entails full coverage of the Batten-1 program development costs. Meanwhile, TX01 remains on track for commercialization by Biocodex and Exeltis, with a planned launch in 2027.

THX Pharma is preparing to release its annual financial results on April 28, 2026, confirming its growth and development trajectory in treatments for rare neurological diseases.